ArticleCancer science2021

HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.

Han Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.